Navigation Links
Dendreon Announces Presentation of PROVENGE Data at the American Society of Clinical Oncology Annual Meeting
Date:5/20/2010

's first autologous cellular immunotherapy product, PROVENGE® (sipuleucel-T), was approved by the FDA in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Dendreon also is developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company is headquartered in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit www.dendreon.com

This news release contains forward-looking statements that are subject to risks and uncertainties. Factors that could affect these forward-looking statements include, but are not limited to, developments affecting Dendreon's business and prospects, including commercialization of PROVENGE. Information on the factors and risks that could affect Dendreon's business, financial condition and results of operations are contained in Dendreon's public disclosure filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. Dendreon cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to Dendreon on the date hereof, and Dendreon undertakes no obligation to revise or update these forward-looking statements to refle
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering
2. Dendreon Announces Pricing of Common Stock Offering
3. Dendreon Appoints Hans Bishop as Chief Operating Officer
4. Dendreon Announces Proposed Public Offering of Common Stock
5. Dendreon Receives FDA Acknowledgement of Complete Response
6. Dendreon Reports Third Quarter 2009 Financial Results and Continuing Progress Toward PROVENGE Commercialization
7. Dendreon Completes Submission of Biologics License Application for PROVENGE
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
10. Dendreon Announces Analyst Day Webcast Presentation to be Held on September 24, 2009
11. Dendreon Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... (PRWEB) June 18, 2013 Demanding industrial ... Lenses engineered of synthetic Sapphire and Glass Ball Lenses, ... from Swiss Jewel Company , of Philadelphia , ... expanding and collimating the light beams without the need ... clarity and natural durability (9 mohs) make it the ...
(Date:6/18/2013)... 2013 RegeneCure announced today ... AMCA Guided Bone Regeneration (GBR) Dental Membrane as a bone ... common problem encountered when patients have a tooth replaced with ... to house the implant. Consequently there is often a need ... natural bone regenerates. The bone substitute material, in turn, needs ...
(Date:6/18/2013)... ALBANY, N.Y. , June 18, 2013 /PRNewswire/ ... that its Burlington, Mass. , ... U.S. Drug Enforcement Administration (DEA) registration to handle ... represents the DEA,s acknowledgement of Burlington,s ... inventory control and documentation. (Logo: ...
(Date:6/18/2013)... Canada (PRWEB) June 18, 2013 ... oversight of pharmaceutical advertising and promotion, and review ... Viewers will learn how to apply these principles ... examples:, ,     The fundamentals on FDA ... and promotional labeling ,     Assessing traditional and ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... TROMS0, Norway and SEOUL, Korea, June 19 ... KAEL-GemVax,today announced the signing of a collaborative agreement to ... for the treatment of,cancer. , ... CEO Jay,Sangjae Kim, "We are delighted to announce this ...
... research from Cincinnati Children,s Hospital Medical Center highlights the critical ... embryonic development on formation of a normal heart and skull. ... Proceedings of the National Academy of Sciences , a ... the gene/protein SHP2 interferes with the normal developmental activity of ...
... Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biopharmaceutical ... HIV-1 (Human Immunodeficiency Virus), and other infectious agents, announced ... cooperative arrangement with Cook County Board President Todd H. ... County Health and Hospitals Systems Board ("Health System"); and ...
Cached Biology Technology:Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy 2Scientists identify gene vital to early embryonic cells forming a normal heart and skull 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 2GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 3GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 4GeoVax Signs HIV/AIDS Vaccine Proposal With Health and Hospital System of Cook County, Illinois 5
(Date:6/18/2013)... chemical modification of DNA and this modification can ... sequence. Until now, scientists believed that this epigenetic ... Today, a team of researchers from the University ... Louis-Jeantet Professor at the Faculty of Medicine, reveals ... that DNA methylation may play both a passive ...
(Date:6/17/2013)... a new virus in patients with severe brain infections ... the virus is responsible for the symptoms of disease. ... 28 out of 644 patients with severe brain infections ... in any of the 122 patients with non-infectious brain ... and central nervous system are often fatal and patients ...
(Date:6/17/2013)... foundations with more modern elements. Using this same approachbut ... Dietrich School of Arts and Sciences have designed a ... storage, and gas transport more efficient and at a ... issue of the Journal of the American Chemical ... builds upon Pitt Associate Professor of Chemistry Nathaniel Rosi,s ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... 12 collaborating institutions have been awarded $24 million in ... for Environmental Implications of Nanotechnology (UC CEIN), which will ... The center, to be housed ... campus, will explore the impact of nanomaterials on life ...
... DURHAM, NC--The National Science Foundation (NSF) and the Environmental ... the Center for Environmental Implications of NanoTechnology (CEINT) to ... Nanoparticles are as much as a million times smaller ... properties compared with larger objects made from the same ...
... University of North Carolina at Chapel Hill School of Medicine ... insulin, the hormone used to treat diabetes. The ... a cure for the millions of people affected by the ... into pluripotent stem cells, or cells that can give rise ...
Cached Biology News:UCLA, partners establish new center on environmental effects of nanotechnology 2UCLA, partners establish new center on environmental effects of nanotechnology 3UCLA, partners establish new center on environmental effects of nanotechnology 4Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 2Duke to lead new NSF, EPA center to study the environmental implications of nanotechnology 3UNC scientists turn human skin cells into insulin-producing cells 2
... new Vivaspin 2 bridges the gap between ... concentrators. This device combines the speed of ... surface and membrane area for superior recoveries ... a choice of PES, Cellulose Triacetate membranes, ...
... II) is involved in translation initiation. PHAS-II ... proteins bind to eIF-4E, the mRNA cap-binding ... in vitro and in cells. Phosphorylation in ... complexes. This allows eIF-4E to bind to ...
Goat polyclonal to Lipocalin 2...
... Vesicular Monoamine Transporter 2 (VMAT2). An antibody ... a major band at ~55 kDa in ... and not in wild type cells (2). ... molecular weight, were also detected and remain ...
Biology Products: